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Abstract 
Aims:  
Understanding the causes of axonal pathology remains a key goal in the pursuit of new therapies to target disease 
progression in MS.  Anterograde axonal transport of many proteins vital for axonal viability is mediated by the 
motor protein KIF5A, which has been linked to several neurological diseases.  This study aimed to investigate the 
expression of KIF5A protein and its associated cargoes: amyloid precursor protein (APP) and neurofilament (NF) 
in post-mortem MS and control white matter and to determine if KIF5A expression is influenced by the presence 
of MS risk single nucleotide polymorphisms (SNPs) identified in the region of the KIF5A gene. 
Methods:  
Using immunoblotting assays we analyzed the expression of KIF5A, APP and NF phospho-isoforms in 23 MS 
cases and 12 controls.   
Results: 
We found a significant reduction in KIF5A and associated cargoes in MS white matter and an inverse correlation 
between KIF5A and APP/NF protein levels. Furthermore, homozygous carriers of MS risk gene SNPs show 
significantly lower levels of KIF5A protein compared to MS patients with no copies of the risk SNPs.  
Conclusions: 
We conclude that reduced expression of axonal motor KIF5A may have important implications in determining 
axonal transport deficits and ongoing neurodegeneration in MS. 
 
Abbreviations used: amyloid precursor protein (APP), Charcot-Marie-Tooth disease type 2A (CMT-2A), 
genome-wide association studies (GWAS), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), hereditary 
spastic paraplegia (HSP), International MS Genetics Consortium (IMSGC), kinesin light chain (KLC), kinesin 
superfamily motor (KIF), multiple sclerosis (MS), neurofilament (NF), neurofilament light (NF-L), neurofilament 
medium (NF-M), neurofilament heavy (NF-H), neuron-specific enolase (NSE), single nucleotide polymorphism 
(SNP), Wellcome Trust Case Control Consortium 2 (WTCCC2), white matter (WM). 
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Introduction 
Multiple sclerosis is characterised pathologically by variable degrees of inflammation and neurodegeneration.  
Axonal loss in both active and chronic white matter (WM) lesions is a key finding of numerous pathological 
studies and is widely believed to be the substrate for irreversible disability occurring in progressive MS [1, 2].  
Recent studies have highlighted the presence of early axonal injury in the brain and spinal cord and the potential 
consequences on long-term axonal viability and neuronal function [3].  Understanding axonal disease pathology 
remains a key goal in the pursuit of new therapies to attenuate MS disease progression. 
Axons require a highly advanced protein transport system due to their high energy demand and the long distances 
they cover in the CNS.  Anterograde axonal transport is largely mediated by kinesin superfamily motor (KIF) 
proteins which hydrolyse ATP in order to generate motile forces to shift associated cargoes along the axon via 
microtubule tracks [4].  There are 45 known members of the KIF family, 38 of which are neuronally enriched [5].  
KIFs exist as homo- or heterodimers and can dimerise to form heterotetramers.  All KIFs contain a microtubule 
binding domain and an ATP-hydrolysing motor domain, which is well conserved between family members.  
Protein cargo specificity is determined by the KIF carboxy tail domain [6].  KIF function is integral to the entire 
CNS transport system and several axonal KIFs have been linked to MS susceptibility [7-9]. We have previously 
reported reduced KIF, (KIF1B, KIF5A and KIF21B), mRNA and protein expression in MS non-lesional grey 
matter.  Notably, our results suggested reduced expression of KIF5A may have particular relevance to MS axonal 
pathology [10]. 
Conventional kinesin I was first discovered in 1985 in the squid axon [11]. Kinesin I exists as a heterotetrameric 
structure where protein cargoes generally bind indirectly through association with kinesin light chains (KLCs) 
and adaptor proteins, bound to the carboxy terminal [12].  Conventional kinesin I, now more commonly known 
as KIF5, comprises three family members; KIF5A, KIF5B and KIF5C [13].  In humans, KIF5B is ubiquitously 
expressed whereas KIF5A and KIF5C are neuronally enriched [14].   Mutations in KIF5A have been linked to 
several neurological diseases such as hereditary spastic paraplegia (HSP) type 10 (SPG10) [15] and Charcot-
Marie-Tooth disease type 2A (CMT-2A) [16] and it is the most extensively studied member of the KIF5 family.   
More recently, single nucleotide polymorphisms (SNPs) in the region of the KIF5A gene (rs12368653 and 
rs703842), have been linked to MS susceptibility [7, 17]. Interestingly, our previous studies found a significant 
reduction in KIF5A protein expression in non-lesional grey matter in MS patients carrying the rs12368653 SNP 
[10].  KIF5A is responsible for the transport of several cargoes implicated in neurodegenerative conditions 
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including; phosphorylated neurofilaments, mitochondria and amyloid precursor protein (APP) [18-20].  In MS, 
aggregates of APP and various neurofilament phosphoepitopes have been identified pathologically, in the cell 
body and diffusely along the course of the axon, or as large aggregates in transected axons, commonly termed 
axonal ‘spheroids’ [21-23]. . 
In order to better understand disease mechanisms resulting in axonopathy, particularly the abnormal accumulation 
of intracellular proteins, this study aimed to measure KIF5A expression in MS and control white matter and its 
relationship to associated protein cargoes: APP and phosphorylated neurofilament.  This study also aimed to 
analyse potential differences between KIF5A protein expression in MS patients who are carriers of MS risk gene 
SNPs (rs12368653 and rs703842), located in the region of the KIF5A gene, which have been linked to MS 
susceptibility. 
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Materials and methods 
Study Cohort 
Tissue samples for this study were obtained from The MS Tissue Bank, Imperial College London, UK.  The study 
was carried out according to national ethical guidelines and legal regulations.  Experiments were performed on 
snap-frozen and paraffin-embedded tissue samples from 23 cases of neuropathologically confirmed MS and 12 
controls (the deaths of whom were not linked to neurological disease; Table 1).  Analysis of MS white matter 
(WM) tissue encompassed demyelinated areas, subcategorised into active, chronic active and silent lesions. 
Normal appearing WM was also studied. The extent of demyelination and lesion classification was performed 
prior to obtaining tissue by neuropathologists within the MS Tissue Bank. 
 
Tissue dissection and protein extraction 
Slices approximately 1mm in width were cut from each MS and control snap-frozen tissue block using a cryostat 
blade. Whilst on ice, WM was dissected away from grey matter tissue. Protein was extracted from each WM 
sample using the Paris Kit (Ambion™, Life Technologies Ltd; Paisley, UK) according to manufacturers’ 
instructions.  Samples were homogenised using Precellys®24 automated homogeniser (Stretton Scientific; 
Derbyshire, UK) and stored at -80oC until required.   
 
Antibody specificity 
Primary antibodies used for all protein and histological analysis in this study were as follows: rabbit anti-KIF5A 
(Sigma-Aldrich Ltd; Dorset, UK; HPA004469),   mouse anti-GAPDH (Abcam; Cambridge, UK; AB9484); rabbit 
anti-NSE (Abgent; San Diego, USA; AP3589A), mouse anti-CNPase (Sigma-Aldrich Ltd; Dorset, UK; C-5922), 
mouse anti-GFAP (Millipore; Hertfordshire, UK; IF03L), mouse anti-APP (Zymed; Life Technologies Ltd; 
Paisley, UK; 13-0200), mouse anti-NF-70 (Millipore; Hertfordshire, UK; MAB1615), mouse anti-SMI32 
(Cambridge Biosciences;  Cambridge, UK; SMI32-R), mouse anti-SMI31(Cambridge Biosciences SMI31-R), 
mouse anti-SMI34 (Cambridge Biosciences; SMI34-R) and mouse anti-SMI36 (Cambridge Biosciences SMI36-
R).  All primary antibodies used for immuno-dot blotting were tested for specificity against chosen antigens using 
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western blotting techniques, as previously documented [10, 22].  All antibodies displayed specific bands as 
described on manufacturer data sheets and/or relative to their reported molecular weights. 
 
Immuno dot-blotting 
Immuno dot-blotting using the following primary antibodies: KIF5A (1:15,000), GAPDH (1:15,000), NSE 
(1:2000), APP (1:500), SMI32 (1:3000), SMI31 (1:5000), SMI34 (1:5000), SMI36 (1:5000) and NF-70 
(1:10,000), was performed as previously described [10].  Protein expression was visualised using a 
chemiluminescence EZ-ECL kit (1:1; Geneflow; Staffordshire, UK) in conjunction with a Biorad Universal III 
Bioplex imager.  Densitometric analysis of protein dots was performed using Image Lab™ 5.0 software (Biorad; 
Hertfordshire, UK).  Values were expressed relative to appropriate loading control proteins; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), neurofilament 70kDa (NF-70) and neuron-specific enolase (NSE). 
 
Genotyping 
Genotype data for all 23 MS patients whose tissue was used in this study were available from the International 
MS Genetics Consortium (IMSGC) and Wellcome Trust Case Control Consortium 2 (WTCCC2) genome-wide 
association studies (GWAS) [17].  Protein data was separated according to patient genotype, based upon those 
who were homozygous or heterozygous carriers of adenine SNPs located in the region of the KIF5A gene 
(rs12368653 and rs703842). 
 
Immunoperoxidase staining of paraffin sections 
7µm sections taken from blocks of the frontal and temporal lobes were stained with rabbit primary antibody 
KIF5A (1:500).  Sections were dewaxed, hydrated, and immersed in 3% hydrogen peroxide in methanol for 30 
minutes to block endogenous peroxidase activity.  Sections were subsequently rinsed in phosphate-buffered saline 
(PBS) and pre-treated with sodium citrate buffer in the microwave (0.01M; pH 6.0; 5 minutes) to unmask antigenic 
sites, followed by additional PBS rinses.  Immunostaining was performed using the Vectastain® Universal Elite® 
ABC Kit (Vector Laboratories; Peterborough, UK).  Sections were blocked in universal blocking serum for 30 
minutes at room temperature before incubation overnight at 4oC with primary antibody diluted in 3% BSA/PBS.  
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Sections were then rinsed in PBS and incubated for 30 minutes with a secondary biotinylated universal antibody 
and 30 minutes with Vectalite ABC complex, followed by a 10 minute incubation with 3,3’-diaminobenzidine 
(DAB) and 0.01% H2O2. Sections were washed in water, immersed in copper sulphate DAB enhancer (4 minutes), 
counterstained with Gills haematoxylin (Sigma-Aldrich Ltd), dehydrated, cleared and mounted. Controls in each 
run included sections incubated overnight in PBS instead of the primary antibody. 
 
Immunofluorescence staining of paraffin sections 
7µm sections taken from blocks of the frontal and temporal lobes were co-stained with primary antibody rabbit 
KIF5A (1:200) combined with mouse APP, CNPase and GFAP (all 1:200).  Sections were dewaxed, hydrated, 
and immersed in 5mM copper sulphate/50mM ammonium acetate for 1 hour to block auto-fluorescence. Sections 
underwent pre-treatment with sodium citrate buffer in the microwave (0.01M, pH 6.0, 5 minutes) to unmask 
antigenic sites, followed by PBS rinses.  Section were blocked using 10% normal goat serum (NGS)/0.1% 
triton/PBS for 1 hour at R/T.  Sections were subsequently incubated overnight in primary antibodies diluted in 
blocking solution.  After PBS rinses sections were incubated in Alexa fluor® secondary antibodies (Invitrogen, 
Life Technologies Ltd; Paisley, UK); goat anti-rabbit 555 (IgG) and goat anti-mouse 488 (IgG) (both 1:500) for 
45 minutes at room temperature in the absence of light, before mounting in Vectashield with DAPI (Vector 
Laboratories) for nuclei identification.  Images were acquired using an inverted Leica CTR 6000 fluorescence 
microscope (Leica Microsystems Ltd; Milton Keynes, UK) and merged with Leica Application Suite Advanced 
Fluorescence (LAS AF) software. 
 
Statistical Analysis 
Statistical analysis of data employed a regression model using Stata v12 (StataCorp LP; Texas, USA), which 
allowed for any correlation among multiple sections coming from the same brain (cluster option). Non-parametric 
bootstrap analysis was used to estimate standard errors and confidence intervals to account for possible non-
normality of the parameter's distribution.  All Graphs were generated using GraphPad Prism5™ (GraphPad 
Software Inc.; San Diego, USA).  Linear regression, correlation and Student’s t-test were also performed on 
PRISM 5 for patient cohort analysis of age and post-mortem delay of the tissue.  For all tests, values of p<0.05 
were considered statistically significant.  
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Results 
Sample cohort variances 
The study cohort of patient clinical histories (Table 1) was analysed to determine any potential effect of age or 
post-mortem delay of tissue on protein expression.  There was no significant difference in the mean post-mortem 
delay of tissue collection between control (21 hrs +/- 8 hrs) and MS patients (17 hrs +/- 7 hrs) (p=0.13; Table 1).  
However, there was a significant difference in the mean age of control (72 yrs) and MS patients (50 yrs) (p<0.001; 
Table 1), related to the high variability in MS disease course. Further linear regression analysis revealed no 
significant effect of patient age on KIF5A, APP and SMI31 protein expression in control and MS cases, when 
normalised to both GAPDH and NSE (data not shown). 
 
Reduced KIF5A expression in MS white matter 
The immuno-dot blot technique was used to collect data on KIF5A protein expression in the cohort and protein 
levels normalised to respective ubiquitous house-keeping proteins GAPDH and neuronal-specific NSE. The 
results showed a significant reduction in KIF5A protein expression in MS WM compared to control, when 
normalised to GAPDH (p<0.05) and NSE (p<0.001; Figure 1A).  Further segregation of MS WM data into lesion 
subtypes, pre-defined by immunohistochemical analysis, revealed a significant reduction in KIF5A protein 
expression in active (p<0.001; normalised to GAPDH and NSE), chronic active (p<0.01; normalised to NSE) and 
silent (p<0.001; normalised to NSE), WM lesions compared to control.  KIF5A expression was also significantly 
reduced in non-lesional normal appearing WM compared to control, when normalised to GAPDH (p<0.01) and 
NSE (p<0.05; Figure 1B). 
 
Altered expression of associated KIF5A protein cargoes in MS white matter  
In addition to measuring KIF5A expression, we analysed the expression of phosphorylated neurofilament (NF), 
which is known to be vital in maintaining axonal structure and integrity. We performed immunoblotting using the 
well-characterised Sternberger monoclonal antibody SMI31, which is directed against phosphorylated epitopes in 
the NF-H and NF-M subunit. The results showed a significant reduction in phosphorylated neurofilament (SMI31) 
protein expression in MS WM compared to control, when normalised to GAPDH (p<0.01) and NSE (p<0.001; 
Figure 2A).  Furthermore, segregation of the data into MS lesion subtypes showed a significant reduction in 
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phosphorylated neurofilament across all WM lesion types: active (p<0.05; normalised to GAPDH and NSE), 
chronic active (p<0.05; normalised to NSE) and silent (p<0.001 normalised to GAPDH; p<0.01 normalised to 
NSE), when compared to control WM. Phosphorylated neurofilament expression was also reduced in non-lesional 
normal appearing WM compared to control, when normalised to GAPDH and NSE (p<0.01; Figure 2B).  
Additionally, we analysed protein expression of APP but found no difference between MS and control, when 
normalised to GAPDH (p=0.55) and NSE (p=0.06; data not shown). Expression of KIF5A appeared to be almost 
exclusively axonal; co-staining of KIF5A and CNPase (an oligodendrocyte marker) was absent and co-staining 
of KIF5A and GFAP (an astrocyte marker) was minimal across control, MS lesional and MS NAWM (data not 
shown). 
 
Correlation analysis was performed in order to elucidate any relationship between KIF5A expression and its well- 
characterised cargoes; phosphorylated NF and APP. Cargo proteins normalised to neuronal NSE were correlated 
against KIF5A protein normalised to ubiquitous GAPDH to avoid the occurrence of a spurious correlation [24].  
Interestingly, the correlation coefficients revealed a moderate negative correlation, both of which were highly 
significant, between KIF5A and both cargoes: SMI31 (Spearman r = -0.32; p<0.01; Figure 3A) and APP (Pearson 
r = -0.37; p<0.01; Figure 3B). This suggests that lower levels of KIF5A are associated with higher levels of SMI31 
and APP in the WM, which could be linked to pathological protein accumulations found commonly in MS axons.  
Indeed, immunoperoxidase and immunofluorescence staining performed on paraffin-embedded sections from 
active lesions in MS white matter revealed the presence of KIF5A positive axonal swellings and co-positive 
KIF5A/APP spheroids (Figure 3C). 
 
Variation in expression of neurofilament phospho-forms in MS white matter 
Neurofilaments exist in several phospho-forms and are commonly found pathologically in MS tissue to be 
dephosphorylated or hyperphosphorylated.  NF-70 is a marker for the neurofilament light chain (NF-L), which is 
phospho-independent but is required for the assembly of the NF heteropolymer containing NF-M or NF-H and is 
therefore deemed a suitable marker for total NF expression. Neurofilaments are vital for axonal structure and 
integrity and our results have shown a significant reduction in total NF in MS compared to control when 
normalised to NSE (p<0.01; Figure 4A). In addition, total NF expression was reduced across MS lesion types 
(active; p<0.01 and silent; p<0.001) and NAWM (p<0.01), compared to control, when normalised to NSE (Figure 
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4B). This gives us insight into total axon loss in MS WM. Due to their pathological links with axon pathology 
and MS, we investigated the expression of several NF phospho-forms using a panel of highly specific Sternberger 
monoclonal antibodies, normalised to both general neuronal marker NSE and axonal neurofilament marker NF-
70.  There was no significance difference in phosphorylated NF-M/NF-H expression (SMI31) when normalised 
to total NF (NF-70; Figure 5A). SMI36, a maker of phosphorylated NF-H, was significantly reduced in MS 
compared to control when normalised to NSE (p<0.001; Figure 5B) but not significantly different from control 
when normalised to NF-70 (Figure 5C).   
Like SMI31, SMI34 is a marker of phosphorylated NF-M and NF-H but has also been implicated as a pathological 
hallmark of NF-H hyperphosphorylation in MS cell bodies and axons [22, 23] and in neurofibrillary tangles in 
Alzheimer’s Disease [25]. Interestingly, we found a significant reduction in SMI34 expression in MS compared 
to control when normalised to NSE (p<0.05; Figure 5D) and conversely, a significant increase in SMI34 
expression in MS compared to control when normalised to total NF (p<0.05; Figure 5E). Similarly, SMI32, a 
marker of dephosphorylated NF-H, is significantly reduced in MS compared to control, when normalised to NSE 
(p<0.05; Figure 5F) but significantly increased when normalised to total NF (p<0.01; Figure 5G). These results 
point towards a general loss of NF in MS WM with remaining axonal NFs more susceptible to 
hyperphosphorylation and dephosphorylation. 
 
Differential expression of KIF5A protein and dephosphorylated neurofilament in patient carriers of MS risk 
SNPs rs12368653 and rs703842. 
Genotype data for all 23 MS cases studied was made available through IMSGC and WTCCC2 GWAS studies 
[17]; based on the discovery of MS risk SNPs rs12368653 and rs703842, located in the region of the KIF5A gene.  
These SNPs are found more frequently in MS patients compared with the general population and therefore are 
believed to confer disease susceptibility.  KIF5A data separated according to patient genotype revealed a 
significant decrease in KIF5A protein expression in patients who are homozygous (AA; p<0.01) or heterozygous 
(AG; p<0.05) carriers of the rs12368653 risk gene SNP compared with patients who carry no copies (GG), when 
normalised to GAPDH (Figure 6A).  Similarly, MS carriers of the rs703842 risk gene SNP have significantly 
lower levels of KIF5A protein compared to patients with no copies (GG), when normalised to GAPDH (AA; 
p<0.01, AG; p<0.01) and NSE (AA; p<0.001, AG; p<0.001) (Figure 6B). Interestingly, combined rs12368653 
and rs703842 risk SNP data shows patients with varying frequencies of adenine substitutions (1-4) have decreased 
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KIF5A protein expression compared to homozygous guanine carriers, when normalised to GAPDH (GG/AG; 
p<0.01, AG/AG; p<0.01, AA/AA; p<0.001; all compared to GG/GG; Figure 6C) and NSE (GG/AG; p<0.001, 
AG/AG; p<0.01, AG/AA; p<0.05; AA/AA; p<0.001; all compared to GG/GG; Figure 6D). In addition, we 
analysed expression of dephosphorylated NF, a pathological hallmark of MS, according to MS genotype. The 
results showed a significant increase in dephosphorylated NF expression in patients heterozygous (AG/AG; 
p<0.05) or homozygous (AA/AA; p<0.05) for both the rs12368653 and rs703842 risk SNP, when compared to 
patients with no copy of either SNP (GG/GG; Figure 7). 
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Discussion 
Understanding how axonal transport deficits contribute to MS pathology is an emerging field [26].  In the present 
study, we compared post-mortem WM tissue from control patients with no sign of neurodegenerative disease to 
MS cases; mainly with late-stage secondary progressive disease and including different types of inflammatory 
lesions and normal-appearing WM.  Our results showed a significant decrease in KIF5A protein expression in MS 
WM compared to control.  We also investigated KIF5A protein expression in relation to inflammation by 
comparing KIF5A expression in lesional- and normal-appearing white matter.  When compared with control, there 
is a significant reduction in KIF5A protein expression across several lesions types with varying degrees of 
inflammatory infiltrates: active, chronic active and silent, and also in normal-appearing white matter. This 
suggests that reduced KIF5A expression in MS not only occurs in acute inflammatory lesions but may be part of 
a widespread neurodegenerative pathological process. Moreover, we have previously shown reduced KIF5A 
expression in non-lesional MS grey matter [10].   
The importance of KIF5A-mediated axonal transport has been highlighted in numerous studies.  Knock-out of the 
kif5a gene in a mouse model has proven neonatally lethal and  targeting of the kif5a gene postnatally in the same 
model, using a synapsin-promoted Cre-recombinase transgene, caused neurofilament accumulation in peripheral 
sensory neuronal cell bodies, reduced axon calibre, axon loss and hind limb paralysis [18].  More recently, studies 
in zebrafish have found kif5a to be essential for mitochondrial localisation in the axon, with zebrafish mutants 
displaying axonal degeneration [27].  We hypothesise that reduced KIF5A expression affects axon viability 
through disrupted transport of intracellular cargoes, such as neurofilaments, mitochondria and APP. Our results 
demonstrated a significant reduction in phosphorylated neurofilament (NF-M and NF-H) expression in MS 
lesional WM and NAWM, compared with control.  Neurofilament phosphorylation in the axon is vital for 
maintaining axonal viability.  The three main neurofilament subunits: NF-light (NF-L; 68kDa), NF-medium (NF-
M; 150kDa) and NF-heavy (NF-H; 190-210kDa) co-assemble to form type IV intermediate filaments; one of the 
main cytoskeletal components of the axon. The C-terminal region in the NF-M and NF-H subunit contains 10-15 
and 40-50 lysine-serine-proline (KSP) repeats respectively, which act as phosphorylation sites.  These 
phosphorylation sites are regulated through the activation of proline-directed kinases which are active in both the 
cell body and proximal axon [28].  Phosphorylation of NF-M and NF-H KSP repeats within the C-terminal side 
arms increases the charge based repulsion of neighbouring filaments, causing an overall increase in interfilament 
spacing and axonal calibre, which is important in optimising axonal saltatory conduction [29]. Reduced NF 
phosphorylation within the axon may decrease axonal calibre and hence viability in MS. Historically, abnormal 
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neurofilament phosphorylation has been identified and associated with axonal pathology in MS [21, 23]. 
Therefore, in this study we used a panel of well-characterised antibodies to NF phospho-isoforms to determine 
any changes in NF phosphorylation states in addition to our findings of decreased phosphorylated neurofilament 
in MS WM. To achieve this, we normalised protein expression of total NF and NF phospho-isoforms to NSE, 
which is ubiquitously expressed in neurons. The results showed a net loss of total NF and NF phospho-isoforms 
in MS neurons compared to control, consistent with the process of axonal loss that is known to occur in the disease. 
In addition, we normalised protein expression of NF phospho-isoforms to NF-70 (NF-L subunit) for analysis of 
NF-specific changes within the axon. NF-M and NF-H need to be in the presence of the NF-L subunit to form 
intermediate filaments [29]. NF-L head domain phosphorylation in the cell body inhibits NF assembly and its 
dephosphorylation is necessary to allow polymerisation of NF proteins (NF-L, NF-M and NF-H), prior to their 
transport into the axon. When normalised to NF-70, phosphorylated NF levels in MS WM were not significantly 
different from control but levels of NF hyperphosphorylation (SMI34) and dephosphorylation levels (SMI32) 
were significantly increased in MS.  This finding is in keeping with previous documentation of NF 
dephosphorylation and hyperphosphorylation in MS [21, 22, 30].  The aberrant phosphorylation status of NFs in 
MS axons could be attributed to dysregulated transport via KIF5A.  
To further investigate this hypothesis we correlated protein expression of phosphorylated NFs with KIF5A 
expression in MS patients and found a significant negative correlation, suggesting that lower levels of KIF5A 
leads to an accumulation of phosphorylated NF.  We further studied protein expression of APP, another well-
characterised cargo of KIF5A.  We saw no significant difference in overall APP expression in MS WM compared 
to control but did find aggregates of APP on immunohistochemistry [31]. Evidence suggests that accumulation of 
APP within axons relates to impaired axonal transport. In MS there is no suggestion that APP expression is altered 
and our findings are in keeping with this. We did find a significant inverse correlation between KIF5A and APP 
expression which supports the hypothesis that reduced KIF5A expression relates to APP accumulation. APP is a 
type I transmembrane protein with suspected roles in cell adhesion, regulating gene expression  and iron export 
[32].  It is thought in axonal transport that APP acts as a cargo receptor for other binding proteins and that fast 
anterograde axonal transport of APP towards the synapse via KIF5A is mediated through KLC association with 
APP-containing vesicles [19].  Historically, APP accumulation has been identified pathologically in MS active 
and chronic lesions [33].  Immunofluorescence staining performed on paraffin-embedded sections in this study 
confirmed the presence of co-stained KIF5A/APP-positive spheroids in MS active lesions and NAWM.  The 
reasons behind APP accumulation in MS remain elusive but we hypothesise accumulation is influenced by 
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deficiencies in anterograde transport, potentially through reduced motor protein KIF5A expression and/or  
inflammatory  mediators affecting KIF5A binding affinity for its cargo [34].  Large protein accumulations in the 
axon, comprising both NFs and APP, are likely to hamper existing transport processes, likened to an intracellular 
‘traffic jam’ [35].  With increasing axonal blockages and reduced protein transport the energy demands of the cell 
will not be met, resulting in increased reactive oxygen species production; lipid peroxidation, neurofilament cross-
linking and eventual axon atrophy and net neuronal loss [36, 37]. 
Taken together, our results suggest that MS WM areas with higher levels of KIF5A are associated with less 
accumulation of APP and phosphorylated neurofilament. Furthermore, our previous studies in MS non-lesional 
grey matter have shown a significant positive correlation between KIF5A expression and patient disease duration, 
suggesting increased survival time that we postulate is partially attributed to maintained axonal cytoskeletal 
transport mechanisms [10]. 
Recent GWAS have identified risk SNPs in the region of the KIF5A gene (rs12368653 and rs703842) which 
confer susceptibility to MS [7, 17].  The rs12368653 SNP is an intronic adenine substitution (predicted in a 
transcription factor binding site), in the AGAP2 gene (ArfGAP with GTPase domain, ankyrin repeat and PH 
domain 2), upstream of the KIF5A gene by approximately 0.2Mb, which does not alter the amino acid sequence. 
The rs12368653 SNP is downstream of the rs703842 SNP by less than 0.1Mb. The rs703842 SNP is a missense 
mutation (predicted in the transcription start site/enhancer region), in the CYP27B1 gene (cytochrome P450, 
family 27, subfamily B, polypeptide 1), upstream of the KIF5A gene by approximately 0.3Mb. The rs703842 
nonsynonymous SNP is an adenine substitution that causes a change in the amino acid sequence from an isoleucine 
to threonine. Linkage disequilibrium is relatively strong between certain SNPs and therefore the non-coding 
regions within several genes close can affect disease susceptibility [38, 39].  Single nucleotide polymorphisms 
that are not in protein-coding regions can still affect gene splicing, transcription factor binding, mRNA 
degradation, or the sequence of non-coding RNA. The rs12368653 and rs703842 SNPs form part of a locus control 
region:  a group of multiple cis-acting elements, including enhancers, silencers and insulators which are involved 
in regulating an entire locus or gene cluster [7]. 
We have previously shown reduced KIF5A protein expression in MS patients with the rs12368653 risk gene SNP 
in non-lesional grey matter [10]. Our results in white matter show patients who are either heterozygous or 
homozygous carriers of the rs12368653 or rs703842 risk gene SNP have significantly lower levels of KIF5A 
protein expression when compared to MS patients who carry no copies of the risk gene SNP.  Moreover, 
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combining genotype data for both the rs12368653 and rs703842 risk SNPs suggest any number of adenine 
substitutions can decrease KIF5A protein expression in MS patients.  Mutations in KIF5A have previously been 
linked to both CMT-2A and HSP.  A missense mutation in the KIF5A gene (N256S) causes an autosomal dominant 
form of HSP (SPG10), which has been implicated in disturbed intracellular axonal transport and is characterised 
by axonal loss in the corticospinal tract [15, 40].  Due to similarities in disease phenotype between MS and HSP, 
one genotype study analysed 68 SNPs across 11 genes linked to HSP in a MS cohort, including SNPs in the region 
of the KIF5A gene.  The data revealed no significant effect of HSP SNPs on MS susceptibility but it did correlate 
SNPs in the region of KIF5A to MS patient clinical outcomes, with some initial differences found in the frequency 
of two SNPs (rs2620678 and rs775245) between relapsing-remitting and secondary progressive patients [41].  
These findings imply SNPs in the region of the KIF5A gene may have an effect on MS disease course.  In light of 
this study and our current findings we hypothesise that carriers of the rs12368653 and rs703842 MS risk gene 
SNP may have a more severe axonal pathology due to lower KIF5A protein expression and consequently, reduced 
and/or dysregulated axonal transport. In support of this hypothesis our study also found a significant increase in 
dephosphorylated NF expression in MS patients who are heterozygous or homozygous carriers of both the 
rs12368653 and rs703842 risk SNP. Neurofilament dephosphorylation in axons has long been established as a 
pathological hallmark of dysregulated axonal transport and neuronal damage in MS [21, 30]. 
 
Overall, this study has shown a significant reduction in KIF5A protein expression in MS white matter both in 
inflammatory lesions and non-inflammatory areas, which correlate with levels of important axonal cargoes 
implicated in the disease; APP and phosphorylated NF.  For future studies it would be interesting to ascertain the 
functional relevance of reduced KIF5A expression both in vitro and in vivo on axonal transport rates and axonal 
blockages, to decipher potential differences in KIF5A-mediated axonal pathology in MS; in the presence and 
absence of inflammation.  Our findings that link KIF5A protein levels to patient genotype, based on the occurrence 
of MS risk SNPs in the region of the KIF5A gene, are interesting and warrant further investigation in larger study 
cohorts in order to generate an in-depth picture of the potential impact of MS genotypes on disease prognosis. 
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Figure Legends 
 
Figure 1. Reduction in KIF5A protein expression in MS patient white matter. (A): protein levels derived 
from immunoblotting show a significant reduction in motor protein KIF5A expression in MS white matter (WM) 
(n=23) compared to control WM (n=12), when normalised to GAPDH and NSE. (B): data categorised according 
to lesion types shows a significant reduction in KIF5A protein expression in active lesions (n=15) compared to 
control, when normalised to GAPDH and NSE; and in chronic active (n=16) and silent (n=16) lesions, when 
normalised to the neuronal protein NSE. KIF5A protein expression is also significantly reduced in MS normal 
appearing white matter (NAWM; n=15) compared to control, when normalised to GAPDH and NSE. Results 
expressed as +/- SEM. * p<0.05, ** p<0.01, *** p<0.001. GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; 
KIF5A: kinesin superfamily protein 5A; MS: multiple sclerosis; NAWM: normal appearing white matter; NSE: 
neuron-specific enolase; SEM: standard error of the mean. 
 
Figure 2. Reduction in neurofilament protein expression in MS patient white matter. (A): protein levels 
derived from immunoblotting show a significant reduction in KIF5A-associated cargo SMI31 (phosphorylated 
NF-M and NF-H subunit) expression in MS white matter (WM) (n=23) compared to control WM (n=12), when 
normalised to GAPDH and NSE. (B): data categorised according to lesion types shows a significant reduction in 
SMI31 protein expression in active (n=15) and silent (n=16) lesions compared to control, when normalised to 
GAPDH and NSE; and in chronic active lesions (n=16), when normalised to the neuronal protein NSE. SMI31 
protein expression was also significantly reduced in MS normal appearing white matter (NAWM; n=15) compared 
23 
 
to control, when normalised to GAPDH and NSE. Results expressed as +/- SEM. * p<0.05, ** p<0.01, *** 
p<0.001. GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; KIF5A: kinesin superfamily protein 5A; MS: 
multiple sclerosis; NAWM: normal appearing white matter; NF-M: neurofilament medium; NF-H: neurofilament 
heavy; NSE: neuron-specific enolase; SEM: standard error of the mean. 
 
Figure 3. Relationship between transport motor protein KIF5A and associated cargoes; APP and NF in MS 
patients.  (A): protein results obtained from immunoblotting show a significant negative correlation between 
KIF5A protein levels normalised to GAPDH and SMI31 (NF-M and NF-H subunit), levels normalised to NSE 
(n=77). (B): significant negative correlation between KIF5A protein levels normalised to GAPDH and APP 
protein levels normalised to NSE (n=72). Values are expressed as the mean +/- 95% CI. ** p<0.01. (C): 
immunoperoxidase staining of frontal lobe active lesion sections from paraffin-embedded MS tissue show KIF5A 
immunopositive axons in MS WM and the presence of KIF5A-positive axonal swellings (i) and spheroid 
formation (ii), highlighted by black arrows. Immunofluorescence staining of paraffin-embedded MS sections 
confirms immunonegative staining of control WM for spheroids (iii) and immunopositive spheroid staining in MS 
NAWM (iv) and active lesion (v). Enlarged images of MS active lesion spheroids denoted by the white box (v) 
confirm immunopositive co-staining of KIF5A (red; va) and APP (green;vb) and immunonegative staining for the 
nuclear marker DAPI (blue; vc), circled in white. Scale bar 50µM. APP: amyloid precursor protein; CI: confidence 
interval; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; KIF5A; kinesin superfamily protein 5A; MS: 
multiple sclerosis; NAWM: normal-appearing white matter; NF-M: neurofilament medium; NF-H; neurofilament 
heavy; NSE: neuron-specific enolase; WM: white matter. 
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Figure 4. Reduced total neurofilament expression in MS white matter. (A): Protein levels derived from 
immunoblotting show a significant reduction in total neurofilament (NF-70) expression in MS WM (n=23) 
compared with control (n=12), when normalised to neuronal marker NSE. (B): data categorised according to 
lesion types shows a significant reduction in NF-70 protein expression in active (n=14) and silent (n=14) lesions 
and in NAWM (n=14) compared to control, when normalised to NSE.  Results expressed as +/- SEM. * p<0.05, 
** p<0.01, *** p<0.001. KIF5A: kinesin superfamily protein 5A; MS: multiple sclerosis; NAWM: normal 
appearing white matter; NF: neurofilament medium; NSE: neuron-specific enolase; SEM: standard error of the 
mean. 
 
Figure 5. Varying expression of neurofilament phospho-forms in MS white matter. (A): Protein levels 
derived from immunoblotting show no significant difference in SMI31 (NF-M and NF-H) expression in MS 
(n=22) compared with control (n=12), when normalised to total neurofilament marker (NF-70). (B): SMI36 (NF-
H) expression is significantly reduced in MS (n=23) compared to controls (n=12), when normalised to NSE. (C): 
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no significant difference in SMI36 expression in MS (n=23) compared with control (n=12) when normalised to 
NF-70. (D): significant reduction in SMI34 (NF-M and NF-H) expression in MS (n=23) compared to control 
(n=11) when normalised to NSE (E): significant increase in SMI34 expression in MS (n=23) compared with 
control (n=11) when normalised to NF-70. (F): significant reduction in SMI32 (non-phosphorylated NF-H), 
expression in MS (n=23) compared with control (n=11), when normalised to NSE. (G): significant increase in 
SMI32 expression in MS (n=23) compared with control (n=11), when normalised to NF-70. Results expressed as 
+/- SEM. * p<0.05, ** p<0.01, *** p<0.001. MS: multiple sclerosis; NF-70: neurofilament 70; NF-M: 
neurofilament medium; NF-H: neurofilament heavy; NSE: neuron-specific enolase; SEM: standard error of the 
mean. 
 
Figure 6. Influence of MS patient genotype and the presence of risk gene SNPs on KIF5A protein levels. 
Protein data (collected via immunoblotting techniques), was separated according to MS patient genotype (n=23). 
(A): KIF5A protein expression was significantly reduced in patients who are heterozygous (AG; n=9) or 
homozygous (AA; n=7) carriers of the MS risk rs12368653 gene SNP located in the region of the KIF5A gene, 
compared to MS patients with no copies of the SNP (GG; n=7), when normalised to GAPDH. (B): KIF5A protein 
expression was significantly reduced in heterozygous (AG; n=9) and homozygous (AA; n=10) MS carriers of the 
MS risk rs703842 gene SNP located in the region of the KIF5A gene, compared to MS patients with no copies of 
the SNP (GG; n=4), when normalised to both GAPDH and NSE. (C): MS patient data categorised according to 
genotypes containing the presence of both MS risk rs12368653 and rs703842 gene SNPs shows significant 
decreases in KIF5A protein expression in patients with varying copies of the SNPs (GG/AG, n=3; AG/AG, n=6; 
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AG/AA, n=3; AA/AA, n=7), compared to patients with no copies of the SNPs (GG/ GG; n=4), when normalised 
to GAPDH and NSE (D). Results expressed as +/- SEM.  * p<0.05, ** p<0.01, *** p<0.001. AA: homozygous 
adenine; AG: adenine and guanine; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; GG: homozygous 
guanine; KIF5A: kinesin superfamily protein 5A; NSE: neuron-specific enolase; SEM: standard error of the mean; 
SNP: single nucleotide polymorphism. 
 
Figure 7. Increased dephosphorylated neurofilament levels associated with axon pathology, in MS patients 
carrying risk gene SNPs. 
Protein data (collected via immunoblotting techniques), was separated according to MS patient genotype (n=23). 
Dephosphorylated neurofilament (SMI32) expression was significantly increased in patients who are 
heterozygous (AG; n=6) or homozygous (AA; n=7) carriers of the MS risk rs12368653 and rs703842 gene SNPs, 
compared to patients with no copies of either SNP (GG; n=4), when normalised to NF-70.  Results expressed as 
+/- SEM.  * p<0.05, ** p<0.01, *** p<0.001. AA: homozygous adenine; AG: adenine and guanine; GG: 
homozygous guanine; KIF5A: kinesin superfamily protein 5A; NF: neurofilament; NSE: neuron-specific enolase; 
SEM: standard error of the mean; SNP: single nucleotide polymorphism. 
 
 
